Celularity, Moleculin Biotech And 2 Other Penny Stocks Insiders Are Aggressively Buying

Celularity, Moleculin Biotech And 2 Other Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed lower by around 500 points on Monday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3

Celularity

  • The Trade: Celularity Inc. CELU CEO Robert Hariri bought a total of 40,000 shares at an average price of $1.74. To acquire these shares, it cost around $69.6 thousand.
  • What’s Happening: The company recently posted a drop in quarterly earnings..
  • What Celularity Does: Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.

LiveVox Holdings

  • The Trade: LiveVox Holdings, Inc. LVOX CEO John D Dilullo acquired a total of 3,082 shares at at an average price of $1.97. The insider spent around $6.07 thousand to buy those shares.
  • What’s Happening: The company recently posted a wider-than-expected quarterly loss.
  • What LiveVox Does: LiveVox Holdings Inc is a next-generation cloud contact-center-as-a-service (or CCaaS) platform providing service to enterprises, business process outsourcers, and collections agencies.

Dow Dips Around 500 Points, Market Volatility Increases Further

Don’t forget to check out our premarket coverage here .

Cosmos Holdings

  • The Trade: Cosmos Holdings Inc. COSM CEO Grigorios Siokas acquired a total of 801,261 shares at an average price of $0.62. To acquire these shares, it cost around $497.88 thousand.
  • What’s Happening: The company recently posted a narrower quarterly loss.
  • What Cosmos Does: Cosmos Holdings Inc is engaged in the research, development, and commercialization of pharmaceutical products and medicines across the European Union member states. It offers over-the-counter drugs and branded and generic medicines.

Moleculin Biotech

  • The Trade: Moleculin Biotech, Inc. MBRX CEO and President Walter Klemp V acquired a total of 45,000 shares at an average price of $1.28. The insider spent $57.63 thousand to buy those shares.
  • What’s Happening: The company recently reported a wider quarterly loss.
  • What Moleculin Biotech Does: Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates.
Posted In: BiotechnologyHealth CareLong IdeasNewsPenny StocksInsider TradesMarketsTrading Ideas